Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 9/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859434 | 1.00 | RIPK1 (0.44) | RIPK1CCR3ADAM17TRPV1EPHX2 | |
| SCHEMBL840107 | 1.00 | RIPK1 (0.44) | RIPK1CCR3ADAM17TRPV1EPHX2 | |
| SCHEMBL840832 | 0.88 | ADAM17 (0.45) | CCR3ADAM17TRPV1 | |
| SCHEMBL9289728 | 0.87 | RIPK1 (0.46) | RIPK1ADAM17EPHX2ADAM10MMP1 | |
| SCHEMBL9288425 | 0.87 | RIPK1 (0.46) | RIPK1ADAM17EPHX2ADAM10MMP1 | |
| SCHEMBL840847 | 0.81 | RIPK1 (0.51) | RIPK1ADAM17EPHX2ADAM10MMP1 | |
| SCHEMBL840981 | 0.80 | RIPK1 (0.50) | RIPK1ADAM17EPHX2 | |
| SCHEMBL16116406 | 0.80 | ADAM17 (0.43) | RIPK1CCR3ADAM17 | |
| SCHEMBL841174 | 0.76 | RIPK1 (0.49) | RIPK1ADAM17 | |
| SCHEMBL839487 | 0.75 | LDHA (0.55) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331499-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-8324217-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | TRPV1, TRPM2, TRPM6 | RIPK1 3006/4885CCR3 277/4885ADAM17 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.